Christy Arrowood Selected Research

ascrinvacumab

10/2019

A phase Ib study of the combination regorafenib with PF-03446962 in patients with refractory metastatic colorectal cancer (REGAL-1 trial).

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.

Realize the full power of the drug-disease research graph!

Christy Arrowood Research Topics

Disease

3	Neoplasms (Cancer) 01/2021 - 04/2014
3	Colorectal Neoplasms (Colorectal Cancer) 11/2019 - 04/2014
1	Adenocarcinoma 01/2021
1	Pancreatic Neoplasms (Pancreatic Cancer) 01/2021
1	Disease Progression 01/2021

Drug/Important Bio-Agent (IBA)

2	Biomarkers (Surrogate Marker)IBA 01/2021 - 11/2019
2	Capecitabine (Xeloda)FDA Link 11/2019 - 04/2014
1	AZD 6244IBA 01/2021
1	Phosphotransferases (Kinase)IBA 01/2021
1	Mitogen-Activated Protein Kinase 1 (p42 MAP Kinase)IBA 01/2021
1	Protein Isoforms (Isoforms)IBA 01/2021
1	Mitogen-Activated Protein Kinase Kinases (MEKs)IBA 01/2021
1	RNA (Ribonucleic Acid)IBA 11/2019
1	afliberceptIBA 11/2019
1	Monoclonal AntibodiesIBA 10/2019
1	regorafenibIBA 10/2019
1	ascrinvacumabIBA 10/2019
1	Activin Receptors (Activin Receptor)IBA 10/2019
1	Oxaliplatin (Eloxatin)FDA LinkGeneric 04/2014
1	Bevacizumab (Avastin)FDA Link 04/2014
1	Dasatinib (BMS 354825)FDA Link 04/2014

Therapy/Procedure

2	Therapeutics 01/2021 - 11/2019
1	Drug Therapy (Chemotherapy) 11/2019